Overall, these results could be used to set up a panel of the most significant cytokines (IL-8, IL-6, sPD-L1, VEGF, IL-4, TNF-α) to be tested prospectively, balanced by clinical risk factors and in different tumors, with the aim of selecting the best treatment choice according to the patient-tumor relationship. The gene discussed is SPDL1; the disease is neoplasm.